CURE FOR COCAINE ADDICTS ON TRIAL

A vaccine which could help cocaine users kick the habit by making them
immune to its effects has passed its first human trial.

The vaccine, known as TA-CD, works by generating antibodies in the blood
that neutralise the effects of the drug. Developed by the American company,
ImmunoLogic, it was purchased by the British company, Cantab
Pharmaceuticals, which announced the results of the trial at a meeting in
Acapulco, Mexico.

Cambridge-based Cantab said the results were "encouraging". It was tested on
34 cocaine-users in New England. The tests showed the vaccine could produce
the antibodies with no serious side-effects.

Dr Thomas Kosten, who led the trial, said: "I am keen to see this vaccine
programme move forward into more advanced trials. TA-CD offers the potential
for a highly viable approach to a serious problem." The company is planning
to introduce a similar treatment for smokers.